series-b
Stage
2021
Founded
1
Investors
About
ARTBIO Therapeutics is a clinical-stage radiopharmaceutical company focused on developing a new class of alpha radioligand therapies (ARTs) for cancer treatment. The company utilizes lead-212 (Pb212), an optimal alpha-emitting isotope, combined with tumor-specific targets to create highly targeted therapies designed to improve patient outcomes.
Explore ARTBIO Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.